Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy versus endocrine therapy in postmenopausal estrogen receptor-positive primary breast cancer
ISRCTN77234840Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Sep 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, open-label trial of fluorouracil, epirubicin, cyclophosphamide and letrozole in breast cancer (2 arms), sponsored by Imperial College London. Primary endpoint: Clinical response rates. Started Sep 2006; status: completed.
02
Drugs
fluorouracilepirubicincyclophosphamideletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN77234840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77234840.